Zobrazeno 1 - 10
of 46
pro vyhledávání: '"JINGFANG JU"'
Autor:
Jingfang Ju, Yao Zheng, Xianxing Wang, Wenjie Huang, Shixiang Guo, Ga-Ram Hwang, Huaizhi Wang, Jiali Yang, Yunchao Wang, Andrew Fesler
Publikováno v:
Molecular Therapy. Nucleic Acids
Treatment of pancreatic ductal adenocarcinoma (PDAC) remains a clinical challenge. There is an urgent need to develop novel strategies to enhance survival and improve patient prognosis. MicroRNAs (miRNAs) play critical roles as oncogenes or tumor sup
Autor:
Wenlu Xiao, Xiao Zheng, Lujun Chen, Qi Zhou, Jingfang Ju, Jingting Jiang, Wenya Su, Zhigang Wang
Publikováno v:
OncoTargets and Therapy. 12:8139-8149
Background IFIT2 (interferon-induced proteins with tetratricopeptide repeats 2), also known as ISG54, is an important interferon-stimulated gene family protein, which has been confirmed to play a crucial role in anti-cancer as well as anti-virus proc
Autor:
Jingfang Ju, Andrew Fesler
Publikováno v:
Journal of pancreatology
Despite extensive research efforts on diagnosis and treatment, pancreatic ductal adenocarcinoma (PDAC) remains a devastating disease and the third leading cause of cancer-related death in the United States. Resistance to current therapeutic approache
Autor:
Xiao Zheng, Yuanyuan Fu, Juan Liu, Changping Wu, Yaoyu Ying, Yun Ding, Jingting Jiang, Jingfang Ju, Wei Wei
Publikováno v:
Translational Cancer Research
Background B7-H7 is a newly identified member of the B7 immune checkpoint family, but has not been investigated in epithelial ovarian cancer (EOC). This study aimed to determine the B7-H7 expression profile and its potential clinical significance in
Autor:
Jingfang Ju, Andrew Fesler
Despite extensive efforts for over 50 years, resistance to chemotherapeutic treatment remains a significant challenge for many different types of cancer including colon cancer. Chemoresistance presents such a major challenge due to the fact that ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::afa989966bc3b113780edebf3501a34a
https://doi.org/10.1016/b978-0-12-819937-4.00005-4
https://doi.org/10.1016/b978-0-12-819937-4.00005-4
Publikováno v:
Biomarker Research, Vol 6, Iss 1, Pp 1-5 (2018)
Biomarker Research
Biomarker Research
Despite tremendous research efforts focused on diagnosis and treatment, pancreatic ductal adenocarcinoma remains the third leading cause of cancer-related death in the United States, with a 5-year overall survival rate of less than 5%. Although resis
Publikováno v:
Oncotarget
Despite advances in colon cancer treatments, resistance and recurrence remain a significant challenge in treating patients. Novel therapeutic strategies are in urgent need to overcome resistance and improve patient outcomes. MicroRNA based therapeuti
Publikováno v:
Oncotarget
// Ning Wu 1, 2, * , Andrew Fesler 1, * , Hua Liu 1, * and Jingfang Ju 1 1 Department of Pathology, School of Medicine, Stony Brook University, Stony Brook, NY, USA 2 Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Aca
Autor:
Apisri Leamniramit, Song Wu, Andrew Fesler, Dongling Ma, Wenzhe Li, Jie Yang, Jingfang Ju, Haiyan Zhai
Publikováno v:
Oncotarget
// Jie Yang 4, * , Dongling Ma 2, * , Andrew Fesler 1, * , Haiyan Zhai 1 , Apisri Leamniramit 2 , Wenzhe Li 2 , Song Wu 3 and Jingfang Ju 1 1 Translational Research Laboratory, Department of Pathology, Stony Brook University, Stony Brook, NY 11794, U
Autor:
Jingfang Ju, Shixiang Guo, Huaizhi Wang, Yunchao Wang, Yao Zheng, Jiali Yang, Andrew Fesler, Xianxing Wang, Wenjie Huang, Ga-Ram Hwang
Treatment of pancreatic ductal adenocarcinoma (PDAC) remains a clinical challenge. There is an urgent need to develop novel strategies to enhance survival and improve patient prognosis. microRNAs (miRNAs) play critical roles as oncogenes or tumor sup
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbbf1e34c1454f3059bb25210b15312e